Korro Bio (KRRO) Other Non-Current Liabilities (2021 - 2026)
Korro Bio's (KRRO) quarterly Other Non-Current Liabilities came in at $1.5 million in Q1 2026, up 1.39% YoY from $1.4 million in Q1 2025, and down 1.28% on a QoQ basis from $1.5 million in Q4 2025.
Korro Bio (KRRO) Other Non-Current Liabilities (2021 - 2026) Analysis & Trends
Korro Bio (KRRO) has 6 years of Other Non-Current Liabilities data on file, last reported at $1.5 million in Q1 2026.
- Quarterly Other Non-Current Liabilities rose 1.39% year-over-year to $1.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 million (up 1.39% YoY) and the FY2025 annual result came in at $1.5 million, up 0.61% from the prior year.
- Other Non-Current Liabilities retreated to $1.5 million in Q1 2026, from $1.5 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $1.5 million in Q3 2025 to a low of $57000.0 in Q1 2022.
- A 5-year average of $990692.3 and a median of $1.2 million in 2024 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2022 — Other Non-Current Liabilities tumbled 82.56% — and 2025, when it soared 113.67%.
- Tracing KRRO's Other Non-Current Liabilities over 5 years: stood at $79000.0 in 2022, then surged by 1232.91% to $1.1 million in 2023, then surged by 39.79% to $1.5 million in 2024, then grew by 0.61% to $1.5 million in 2025, then dropped by 1.28% to $1.5 million in 2026.
- The last three Other Non-Current Liabilities figures came in at $1.5 million (Q1 2026), $1.5 million (Q4 2025), and $1.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Korro Bio | 231.77 Mn | 116.73 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.50 Mn |
| Mar 31, 2026 | 1.46 Mn |
| Dec 31, 2025 | 1.48 Mn |
| Sep 30, 2025 | 1.53 Mn |
| Jun 30, 2025 | 1.44 Mn |
| Mar 31, 2025 | 1.44 Mn |
| Dec 31, 2024 | 1.47 Mn |
| Sep 30, 2024 | 717,000.00 |
| Jun 30, 2024 | 1.18 Mn |
| Mar 31, 2024 | 893,000.00 |
| Dec 31, 2023 | 1.05 Mn |
| Sep 30, 2022 | 79,000.00 |
| Jun 30, 2022 | 68,000.00 |
| Mar 31, 2022 | 57,000.00 |
| Dec 31, 2021 | 87,000.00 |
| Sep 30, 2021 | 278,000.00 |
| Jun 30, 2021 | 390,000.00 |